Related references
Note: Only part of the references are listed.Epithelial X-Box Binding Protein 1 Coordinates Tumor Protein p53-Driven DNA Damage Responses and Suppression of Intestinal Carcinogenesis
Lina Welz et al.
GASTROENTEROLOGY (2022)
A comprehensive analysis of the diagnostic and prognostic value associated with the SLC7A family members in breast cancer
Liping Yan et al.
GLAND SURGERY (2022)
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Weitong Gao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
Yi-Zhou Jiang et al.
CELL RESEARCH (2021)
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
Yue Gong et al.
CELL METABOLISM (2021)
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D. Miles et al.
ANNALS OF ONCOLOGY (2021)
ENO1 Promotes Lung Cancer Metastasis via HGFR and WNT Signaling-Driven Epithelial-to-Mesenchymal Transition
Hsin-Jung Li et al.
CANCER RESEARCH (2021)
DDIT4 overexpression associates with poor prognosis in lung adenocarcinoma
Li Song et al.
JOURNAL OF CANCER (2021)
PLOD1 promotes cell growth and aerobic glycolysis by regulating the SOX9/PI3K/Akt/mTOR signaling pathway in gastric cancer
Yixin Zhang et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2021)
A review of the mechanism of DDIT4 serve as a mitochondrial related protein in tumor regulation
Fadian Ding et al.
SCIENCE PROGRESS (2021)
A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells
Maxine Umeh-Garcia et al.
CANCER RESEARCH (2020)
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Keisuke Yamamoto et al.
NATURE (2020)
Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance
Shen Zhao et al.
ONCOLOGIST (2020)
Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites
Claudie Bosc et al.
NATURE COMMUNICATIONS (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Bulent Cetin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Seongju Jeong et al.
IMMUNE NETWORK (2020)
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
Martha Foltyn et al.
BRITISH JOURNAL OF CANCER (2019)
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Yi Xiao et al.
CLINICAL CANCER RESEARCH (2019)
被撤回的出版物: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast Cancer (Retracted article. See vol. 30, pg. 2639, 2022)
Cheng-Cao Sun et al.
MOLECULAR THERAPY (2019)
S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells
Kyoko Kikuchi et al.
CELLULAR ONCOLOGY (2019)
BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection
Xueping Yu et al.
FRONTIERS IN IMMUNOLOGY (2019)
LinkedOmics: analyzing multi-omics data within and across 32 cancer types
Suhas V. Vasaikar et al.
NUCLEIC ACIDS RESEARCH (2018)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Y. Bareche et al.
ANNALS OF ONCOLOGY (2018)
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
D. A. Yardley et al.
ANNALS OF ONCOLOGY (2018)
GSCALite: a web server for gene set cancer analysis
Chun-Jie Liu et al.
BIOINFORMATICS (2018)
Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer
Wei Li et al.
CELL METABOLISM (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
GeneMANIA update 2018
Max Franz et al.
NUCLEIC ACIDS RESEARCH (2018)
Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis
Oihana Iriondo et al.
NATURE COMMUNICATIONS (2018)
DNA Damage inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer
Indira Tirado-Hurtado et al.
FRONTIERS IN ONCOLOGY (2018)
Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma
Bin Chang et al.
DIAGNOSTIC PATHOLOGY (2018)
A history of exploring cancer in context
Shelly Maman et al.
NATURE REVIEWS CANCER (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Qinghai Zeng et al.
CLINICAL CANCER RESEARCH (2018)
DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways
Feng Du et al.
CANCER COMMUNICATIONS (2018)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Darshan S. Chandrashekar et al.
NEOPLASIA (2017)
In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies
Joseph A. Pinto et al.
SCIENTIFIC REPORTS (2017)
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Taiwen Li et al.
CANCER RESEARCH (2017)
Emerging role for regulated in development and DNA damage 1 (REDD1) in the regulation of skeletal muscle metabolism
Bradley S. Gordon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
Yi-Rong Liu et al.
CLINICAL CANCER RESEARCH (2016)
A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease
Joseph A. Pinto et al.
NPJ GENOMIC MEDICINE (2016)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis
Peter Horak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer - The California cancer registry, 1999-2004
Monica Brown et al.
CANCER (2008)
REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species
LW Ellisen et al.
MOLECULAR CELL (2002)